Epigenetic Analysis of Regulation of the Inflammasome-activating NLRP3 Gene in Monocytes From Atrial Fibrillation Patients and Controls
NCT ID: NCT04766814
Last Updated: 2024-04-25
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
29 participants
Study Classification
OBSERVATIONAL
Study Start Date
2021-10-22
Study Completion Date
2024-02-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will analyze blood from volunteers to determine whether there is an underlying epigenetic cause of the inflammation of the heart associated with atrial fibrillation (AF) and its progression with age. Confirming the regions of epigenetic elements associated with upregulation of the inflammatory genes will help the investigators in identifying target sites for developing future therapeutic interventions. The investigators propose to confirm the monocyte-cell type specific DNA methylation profile of NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) and determine the age-related and AF-related changes in DNA methylation and expression of NLRP3 in monocytes. This study will provide insights into the epigenetic regulation of NLRP3 in young and elderly patients, as well as in AF patients vs. controls which will help in devising methods of modulating NLRP3 expression and decreasing cardiac fibrosis progression.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart
NCT02885740
Atrial Fibrillation
UNKNOWN
NA
Inflammatory Genomics in Human Carotid Artery Disease
NCT00070668
Cardiovascular Diseases
Atherosclerosis
Carotid Artery Diseases
+1 more
COMPLETED
Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation
NCT00599118
Atrial Fibrillation
ACTIVE_NOT_RECRUITING
Genetic Markers of CHD Risk in Men and Women
NCT00090454
Cardiovascular Diseases
Coronary Disease
Heart Diseases
+2 more
COMPLETED
The Genetic Basis for Atrial Fibrillation
NCT03491202
Atrial Fibrillation
UNKNOWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Blood samples will be collected from 30 female participants as follows: 10 women between the ages of 50 - 80 years diagnosed with AF as evidenced by rhythm strips or written documentation; 10 healthy women subjects between the ages of 50-80 years and 10 healthy women between the ages of 20-30 years.
Participants will be recruited from the Tulane University Cardiology Clinics and also from volunteer research registries. These participants will be asked for consent to draw for another 8 ml (1.5 teaspoons) of blood during routine diagnostic blood draws. These blood samples will be de-identified by the PI upon receipt and no identifiable information will be maintained. Leukocyte subtypes including monocytes, neutrophils and B cells will be isolated from blood and DNA extraction will be carried out from the leukocyte subtypes. These leukocyte DNA samples will be sent to New England Biolabs, Ipswich, Massachusetts for DNA methylation analysis to identify target regions of epigenetic elements associated with upregulation of NLRP3 gene expression that might be related to disease progression with age. Real-Time Polymerase chain reaction (PCR) will be carried out at Tulane Research and Innovation for Arrhythmia Discoveries (TRIAD) Center, Tulane University School of Medicine from RNA extracted from leukocyte subtype to check the level of expression of NLRP3 highly associated with inflammation in AF.
Participants will be recruited from the Tulane University Cardiology Clinics and also from volunteer research registries. These participants will be asked for consent to draw for another 8 ml (1.5 teaspoons) of blood during routine diagnostic blood draws. These blood samples will be de-identified by the PI upon receipt and no identifiable information will be maintained. Leukocyte subtypes including monocytes, neutrophils and B cells will be isolated from blood and DNA extraction will be carried out from the leukocyte subtypes. These leukocyte DNA samples will be sent to New England Biolabs, Ipswich, Massachusetts for DNA methylation analysis to identify target regions of epigenetic elements associated with upregulation of NLRP3 gene expression that might be related to disease progression with age. Real-Time Polymerase chain reaction (PCR) will be carried out at Tulane Research and Innovation for Arrhythmia Discoveries (TRIAD) Center, Tulane University School of Medicine from RNA extracted from leukocyte subtype to check the level of expression of NLRP3 highly associated with inflammation in AF.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Atrial Fibrillation
Arrhythmia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_CONTROL
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient Group
10 women between the ages of 50 - 80 years diagnosed with AF as evidenced by rhythm strips or written documentation.
No interventions assigned to this group
Control Group 1
10 healthy women subjects between the ages of 50-80 year
No interventions assigned to this group
Control Group 2
10 healthy women subjects between the ages of 20-30 years
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects aged 18 or above,
* Control Group scheduled for routine annual health check-up and healthy blood donors without any documentation of cardiovascular disease or other serious immune-related illnesses, such as diabetes, hypertension, autoimmune arthritis etc
* healthy women subjects between the ages of 50-80 years
* healthy women subjects between the ages of 20-30 years.
Study Patients -women between the ages of 50 - 80 years diagnosed with AF as evidenced by rhythm strips or written documentation.
* Control Group scheduled for routine annual health check-up and healthy blood donors without any documentation of cardiovascular disease or other serious immune-related illnesses, such as diabetes, hypertension, autoimmune arthritis etc
* healthy women subjects between the ages of 50-80 years
* healthy women subjects between the ages of 20-30 years.
Study Patients -women between the ages of 50 - 80 years diagnosed with AF as evidenced by rhythm strips or written documentation.
Exclusion Criteria
* Previous left atrial ablation or any type of valvular surgery
* Patients who are taking medications like Ibuprofen, Toradol, Naproxen and other common over-the -counter NSAIDs.
* Women who are pregnant
* Terminally ill patients
* Patients who are taking medications like Ibuprofen, Toradol, Naproxen and other common over-the -counter NSAIDs.
* Women who are pregnant
* Terminally ill patients
Minimum Eligible Age
20 Years
Maximum Eligible Age
80 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Louisiana Clinical and Translational Science (LA CaTS) Center Clinical Research Resources Core
OTHER
Sponsor Role
collaborator
Tulane University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sruti Chandra, PhD
Role: PRINCIPAL_INVESTIGATOR
Tulane University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tulane University Medical Center
New Orleans, Louisiana, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Zhu J, Wu S, Hu S, Li H, Li M, Geng X, Wang H. NLRP3 inflammasome expression in peripheral blood monocytes of coronary heart disease patients and its modulation by rosuvastatin. Mol Med Rep. 2019 Aug;20(2):1826-1836. doi: 10.3892/mmr.2019.10382. Epub 2019 Jun 13.
Reference Type
BACKGROUND
Johansson A, Enroth S, Gyllensten U. Continuous Aging of the Human DNA Methylome Throughout the Human Lifespan. PLoS One. 2013 Jun 27;8(6):e67378. doi: 10.1371/journal.pone.0067378. Print 2013.
Reference Type
BACKGROUND
Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, Hou L, Baccarelli AA, Stewart JD, Li Y, Whitsel EA, Wilson JG, Reiner AP, Aviv A, Lohman K, Liu Y, Ferrucci L, Horvath S. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018 Apr 18;10(4):573-591. doi: 10.18632/aging.101414.
Reference Type
BACKGROUND
Lio CJ, Rao A. TET Enzymes and 5hmC in Adaptive and Innate Immune Systems. Front Immunol. 2019 Feb 12;10:210. doi: 10.3389/fimmu.2019.00210. eCollection 2019.
Reference Type
BACKGROUND
Heinzmann D, Bangert A, Muller AM, von Ungern-Sternberg SN, Emschermann F, Schonberger T, Chatterjee M, Mack AF, Klingel K, Kandolf R, Malesevic M, Borst O, Gawaz M, Langer HF, Katus H, Fischer G, May AE, Kaya Z, Seizer P. The Novel Extracellular Cyclophilin A (CyPA) - Inhibitor MM284 Reduces Myocardial Inflammation and Remodeling in a Mouse Model of Troponin I -Induced Myocarditis. PLoS One. 2015 Apr 20;10(4):e0124606. doi: 10.1371/journal.pone.0124606. eCollection 2015.
Reference Type
BACKGROUND
Sun Z, Vaisvila R, Hussong LM, Yan B, Baum C, Saleh L, Samaranayake M, Guan S, Dai N, Correa IR Jr, Pradhan S, Davis TB, Evans TC Jr, Ettwiller LM. Nondestructive enzymatic deamination enables single-molecule long-read amplicon sequencing for the determination of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution. Genome Res. 2021 Feb;31(2):291-300. doi: 10.1101/gr.265306.120. Epub 2021 Jan 19.
Reference Type
BACKGROUND
Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014 Feb 25;129(8):837-47. doi: 10.1161/CIRCULATIONAHA.113.005119. Epub 2013 Dec 17.
Reference Type
BACKGROUND
Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006 Jul 11;114(2):119-25. doi: 10.1161/CIRCULATIONAHA.105.595140. Epub 2006 Jul 3.
Reference Type
BACKGROUND
Akoum N, Mahnkopf C, Kholmovski EG, Brachmann J, Marrouche NF. Age and sex differences in atrial fibrosis among patients with atrial fibrillation. Europace. 2018 Jul 1;20(7):1086-1092. doi: 10.1093/europace/eux260.
Reference Type
BACKGROUND
Wagstaff AJ, Overvad TF, Lip GY, Lane DA. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. QJM. 2014 Dec;107(12):955-67. doi: 10.1093/qjmed/hcu054. Epub 2014 Mar 14.
Reference Type
BACKGROUND
Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M, Odutayo AA. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ. 2016 Jan 19;532:h7013. doi: 10.1136/bmj.h7013.
Reference Type
BACKGROUND
Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J. 2005 Oct;26(20):2083-92. doi: 10.1093/eurheartj/ehi350. Epub 2005 Jun 23.
Reference Type
BACKGROUND
Hohmann C, Pfister R, Mollenhauer M, Adler C, Kozlowski J, Wodarz A, Drebber U, Wippermann J, Michels G. Inflammatory cell infiltration in left atrial appendageal tissues of patients with atrial fibrillation and sinus rhythm. Sci Rep. 2020 Feb 3;10(1):1685. doi: 10.1038/s41598-020-58797-8.
Reference Type
BACKGROUND
Liu Y, Shi Q, Ma Y, Liu Q. The role of immune cells in atrial fibrillation. J Mol Cell Cardiol. 2018 Oct;123:198-208. doi: 10.1016/j.yjmcc.2018.09.007. Epub 2018 Sep 26.
Reference Type
BACKGROUND
Le Jemtel TH, Samson R, Ayinapudi K, Singh T, Oparil S. Epicardial Adipose Tissue and Cardiovascular Disease. Curr Hypertens Rep. 2019 Apr 5;21(5):36. doi: 10.1007/s11906-019-0939-6.
Reference Type
BACKGROUND
Yamashita T, Sekiguchi A, Iwasaki YK, Date T, Sagara K, Tanabe H, Suma H, Sawada H, Aizawa T. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ J. 2010 Feb;74(2):262-70. doi: 10.1253/circj.cj-09-0644. Epub 2009 Dec 15.
Reference Type
BACKGROUND
Shantsila E, Tapp LD, Wrigley BJ, Pamukcu B, Apostolakis S, Montoro-Garcia S, Lip GY. Monocyte subsets in coronary artery disease and their associations with markers of inflammation and fibrinolysis. Atherosclerosis. 2014 May;234(1):4-10. doi: 10.1016/j.atherosclerosis.2014.02.009. Epub 2014 Feb 20.
Reference Type
BACKGROUND
Budai MM, Varga A, Milesz S, Tozser J, Benko S. Aloe vera downregulates LPS-induced inflammatory cytokine production and expression of NLRP3 inflammasome in human macrophages. Mol Immunol. 2013 Dec;56(4):471-9. doi: 10.1016/j.molimm.2013.05.005. Epub 2013 Aug 1.
Reference Type
BACKGROUND
He G, Tan W, Wang B, Chen J, Li G, Zhu S, Xie J, Xu B. Increased M1 Macrophages Infiltration Is Associated with Thrombogenesis in Rheumatic Mitral Stenosis Patients with Atrial Fibrillation. PLoS One. 2016 Mar 1;11(3):e0149910. doi: 10.1371/journal.pone.0149910. eCollection 2016.
Reference Type
BACKGROUND
Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O'Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003 Nov 18;108(20):2460-6. doi: 10.1161/01.CIR.0000099542.57313.C5. Epub 2003 Oct 27.
Reference Type
BACKGROUND
Nattel S. Molecular and Cellular Mechanisms of Atrial Fibrosis in Atrial Fibrillation. JACC Clin Electrophysiol. 2017 May;3(5):425-435. doi: 10.1016/j.jacep.2017.03.002. Epub 2017 May 15.
Reference Type
BACKGROUND
Misialek JR, Bekwelem W, Chen LY, Loehr LR, Agarwal SK, Soliman EZ, Norby FL, Alonso A. Association of White Blood Cell Count and Differential with the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study. PLoS One. 2015 Aug 27;10(8):e0136219. doi: 10.1371/journal.pone.0136219. eCollection 2015.
Reference Type
BACKGROUND
Van Wagoner DR, Chung MK. Inflammation, Inflammasome Activation, and Atrial Fibrillation. Circulation. 2018 Nov 13;138(20):2243-2246. doi: 10.1161/CIRCULATIONAHA.118.036143. No abstract available.
Reference Type
BACKGROUND
Yao C, Veleva T, Scott L Jr, Cao S, Li L, Chen G, Jeyabal P, Pan X, Alsina KM, Abu-Taha I Dr, Ghezelbash S, Reynolds CL, Shen YH, LeMaire SA, Schmitz W, Muller FU, El-Armouche A, Tony Eissa N, Beeton C, Nattel S, Wehrens XHT, Dobrev D, Li N. Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. Circulation. 2018 Nov 13;138(20):2227-2242. doi: 10.1161/CIRCULATIONAHA.118.035202.
Reference Type
BACKGROUND
Chen H, Zhang X, Liao N, Mi L, Peng Y, Liu B, Zhang S, Wen F. Enhanced Expression of NLRP3 Inflammasome-Related Inflammation in Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):978-985. doi: 10.1167/iovs.17-22816.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-561
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Inflammation as a Predictor in Cardioversion of Atrial Fibrillation
NCT00590525
COMPLETED
Inflammation Markers Over Time in Cardiovascular Disease
NCT00005692
COMPLETED
The Genetic Basis of Atrial Fibrillation (AF)
NCT00248326
COMPLETED
Biomarkers and SNP-polymorphisms in Post-infarction Cardiac Remodeling
NCT04296253
COMPLETED
THE GIRAFFE Study: Genomic Risk Markers for Atrial Fibrillation Following Extended Cardiac Rhythm Monitoring
NCT01970969
COMPLETED
Early Repolarization Syndrome: Define the Risk, Stratify the Coverage and Understand the Causes - Clinical and Genetic Study
NCT02847039
UNKNOWN
Predicting Risk of Atrial Fibrillation and Association With Other Diseases
NCT05837364
COMPLETED
MAP-IDM: Identification of Molecular Markers of Sudden Death at the Acute Phase of Myocardial Infarction
NCT00859300
COMPLETED
Gene-by-Smoking Interactions and Risk of Atherosclerosis - Ancillary to ARIC
NCT00064545
COMPLETED
Identification of Genes Expressed in Atherosclerotic Plaque
NCT00353730
COMPLETED
Epidemiology of Atherosclerosis
NCT00005147
COMPLETED
Molecular Epidemiology of Myocardial Infarction and Stroke in Older Adults - Ancillary to CHS
NCT00078429
COMPLETED
Biochemical Marker to Predict the Recurrence of Atrial Fibrillation After Surgical Maze Procedure
NCT00542659
COMPLETED
Gene Expression Profiling in Subjects With Postoperative Atrial Fibrillation After Cardiac Surgery (GENEXPRO Surg)
NCT00833313
UNKNOWN
Genetic Architecture of Plasma T-PA and PAI-1
NCT00007410
COMPLETED
Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial Fibrillation
NCT05190679
RECRUITING
Atherosclerosis Risk in Communities (ARIC)
NCT00005131
COMPLETED
Pharmacogenetics and Cardiovascular Events
NCT00094198
COMPLETED
Modeling DNA Diversity in Cardiovascular Health/Disease
NCT00005490
COMPLETED
Mapping Novel Disease Genes for Dilated Cardiomyopathy
NCT00046618
COMPLETED
Understanding the Genetic and Hereditary Basis of Atherosclerosis
NCT00344292
COMPLETED
Inflammation, Infection, and Future Cardiovascular Risk
NCT00005496
COMPLETED
Molecular Investigation of Genetic Factors in CArDiovascular Diseases Using an BIOresource of Healthy Volunteers
NCT03038750
TERMINATED
Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia
NCT00005313
COMPLETED
Identification of Genetic Causes of Calcific Aortic Valve Disease
NCT04149600
ACTIVE_NOT_RECRUITING